[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_95":96},"routes/item",{"_9":10},"item",{"_11":12,"_13":14,"_15":16,"_17":18,"_19":20,"_21":-5,"_22":23,"_24":25,"_26":27,"_28":29,"_30":29,"_31":32,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":-5,"_46":47,"_48":-5,"_49":-5,"_50":51,"_52":53,"_54":55,"_56":57,"_58":57,"_59":60,"_61":40,"_62":63},"id","rw50kxop4pzftnpvgt8boxw0n","revision",2,"title","Evofem Biosciences 修订证券购买协议","originalTitle","Evofem Biosciences, Inc. (0001618835) (Filer)","summary","Evofem Biosciences 与 Adjuvant 修订证券购买协议，将可转债到期日调整为 2026 年 12 月 1 日或控制权变更日。协议取消部分积极义务，且未获 Adjuvant 同意不得提前还款。","reason","source",{"_11":85,"_86":87,"_88":89,"_90":57,"_91":92,"_93":94},"links",{"_82":83,"_63":84},"publishedAt","2026-10-15T20:05:33.000Z","discoveredAt","2026-10-15T20:16:06.941Z","timelineAt","category","ai-products","tags",[80,81],"stockSymbols",[79],"score",30,"selected",false,"channel","news","story",{"_72":73,"_15":16},"x","readingMode","full","author","language","body",{"_75":-5,"_63":76,"_77":-5,"_78":40},"outline",[],"relatedStories",[74],"indexable",true,"markdownAvailable","group",{"_64":65,"_43":66,"_67":68,"_69":70,"_71":70},"hasTranslation","bodyLanguage","original","factId","fN056NdowCjc",{"_72":73,"_15":16},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","6ea3e1cf-927e-43ee-a5df-259edc38b1c7",{"_72":73,"_15":16},"zh","

UNITED\nSTATES

SECURITIES\nAND EXCHANGE COMMISSION

Washington,\nD.C. 20549

FORM\n8-K

CURRENT\nREPORT

PURSUANT\nTO SECTION 13 OR 15(d) OF THE

SECURITIES\nEXCHANGE ACT OF 1934

Date\nof Report (Date of earliest event reported): October 9, 2026

EVOFEM\nBIOSCIENCES, INC.

(Exact\nname of registrant as specified in its charter)

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

Delaware	001-36754	20-8527075
(State\n or other jurisdiction	(Commission	(I.R.S.\n Employer
of\n incorporation)	File\n Number)	Identification\n No.)

7770\nRegents Road, Suite 113-618

San\nDiego, California 92122

(Address\nof principal executive offices)

(858)\n550-1900

(Registrant’s\ntelephone number, including area code)

N/A

(Former\nname or former address, if changed since last report)

Check\nthe appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under\nany of the following provisions:

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

☐	Written\n communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting\n material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)

☐	Pre-commencement\n communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))

☐	Pre-commencement\n communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

Securities\nregistered pursuant to Section 12(b) of the Act:

\n \n \n \n \n \n \n \n \n \n \n \n \n

Title\n of each class		Trading\n Symbol(s)		Name\n of exchange on which registered
None

Indicate\nby check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405\nof this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging Growth Company ☐

If\nan emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item\n1.01 Entry into a Material Definitive Agreement

Amendment\nto Securities Purchase Agreement

On\nOctober 9, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology\nFund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fifth amendment (the\n“Fifth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended (the “SPA”,\npursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).

The\nFifth Amendment amends certain provisions within the Securities Purchase Agreement including updating the date that the Notes will be\npayable in full to the earlier of (a) December 1, 2026, (b) at the election of Adjuvant, the date of a consummation of a Change\nof Control (as defined in the Securities Purchase Agreement), and (c) the date of any acceleration of the Notes in accordance with Section\n8 (the “Maturity Date”, as per the Securities Purchase Agreement). The Notes may not be prepaid prior to December 1, 2026\nwithout prior written consent of Adjuvant. The Fifth Amendment also removed certain affirmative covenants as per section 7.1 of the\nSPA.

Item\n9.01. Financial Statements and Exhibits.

(d)\nExhibits

\n \n \n \n \n \n \n \n \n \n \n \n \n

Exhibit\n No.		Description
10.1		Fifth Amendment to Securities Purchase Agreement dated as of October 9, 2026
104		Cover\n Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.

\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n

	EVOFEM\n BIOSCIENCES, INC.

Dated:\n October 15, 2026	By:	/s/\n Saundra Pelletier
		Saundra\n Pelletier
		Chief\n Executive Officer

","zhKind","complete","EVFM","公司与财报","融资","aihot","/items/rw50kxop4pzftnpvgt8boxw0n","https://www.sec.gov/Archives/edgar/data/1618835/000149315226047227/0001493152-26-047227-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","kind","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792281600&sig=7e2c0b2887bde829","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792281600&sig=4a4e737d69fc85ba 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792281600&sig=f06d97a3bb025478 96w","changelogVersion","2026-10-01T08:00"]